Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

Up 0.63p today, is the good news round the corner???

something is rotten here - a 12% move despite sales outweighing buys 3 to 1 ? Are the market makers pushing the price up to flush out sellers because they are short of stock?

I have just been quoted 11.62 to buy just a small quantity and therefore think that all the 11.6 are buys and not sells as reported.
anyone got the current sell price ????

I have noticed that for the past few days, the more and bigger the sells the higher the price is getting. Something is not right somewehere!!!! Who cares as long as this continues It does'nt bother me!!!

Up 1.26 today price now 11.62, if this continues nice and steadily we might be seeing 15p by the end of the week!!!! Goog luck all.

sorry GOOD LUCK ALL!!

According to Iwebsharedealing sell price is showing as 11.25 and buy at 12.00

I do wish the Directors would stop acting like "Ships in the Night"

OOOH look - an upward movement in price on lots of sales - someone wants to flush out sellers and grab their stock - fill ya boots boys!

Th share price is steadily moving up its 0.50p (4.26%) up today. The Directors are taking their time to reveal the results of the trials!!!

Let us hope that they are not going to be as honest as the CEO of PDX who in similar circumstances announced it was a newspaper talk

There is definetly something going on today, lots of buys going through, does someone out there know something I don't know?????

i am one of the buys . wish i had got in when shares tipped them a few weeks ago . it does look very exciting at the moment.looking for 20p by christmas.

Bosley I bought them the first week shares recommeded them and I also topped up today, up 0.63p looking good so far!! Fingers crossed and all the best!!

lets hope as oakapples says that the price movement this week is not anticipating a positive statement that never happens.on a more positive note any good news could take the share price a long way

Rumour circulating their could be an annoucement on Monday. Hence the volume buying this week.

Does anyone know for sure, is there going to be an anouncement tomorrow???

Probably not imho

momentum - wrong!!!!!

I want to know though despite the lioss announced - why is it that there is no 'momentum' off the back of the phase iii results - are [people expecting the worst or have they deliberately delayed the results of the trials to sogften the blow from the financials?

CeNeS Pharmaceuticals PLC
20 September 2004


CeNeS Reports 2004 Interim Results

Cambridge, UK 20 September 2004 - CeNeS Pharmaceuticals plc (AIM: CEN) ('CeNeS'
or 'the Company') today announced its unaudited interim financial results for
the six months ended 30 June 2004.


Operational highlights

M6G successfully completes Phase III trial in post-operative pain (see
separate press release dated today)
CNS 5161 for neuropathic pain entered a Phase II trial.


Financial highlights

Net loss for the first half of 2004 of 2.3m (H1 2003: profit 0.9m
including 3.2m profit on sale of pharmaceutical products).
Cash balances at end of June 2004 of 6.1m (June 2003: 8.2m).


Corporate matters

Alan Smith, Chairman of Acambis Plc and Avlar Bioventures Limited
appointed as a Non-executive Director.
Piper Jaffray Ltd and Nomura International plc appointed nominated
advisor (NOMAD) and nominated broker respectively.



Commenting on the results, Alan Goodman, Chairman of CeNeS Pharmaceuticals plc,
said:


'The Board is delighted to report that CeNeS has continued to successfully meet
its key strategic objectives in 2004.


We are particularly pleased with the announcement today of the positive M6G
Phase III results in post-operative pain. CeNeS retains all global marketing
rights to M6G and is well placed to capture the potential commercial value in
this novel, late stage pain product.

Additionally, CNS 5161 has commenced a Phase II trial in neuropathic pain with
patient recruitment underway. Furthermore, the Company's pre-clinical short
acting sedative and discovery Parkinson's disease programmes are also
progressing in line with expectations. CeNeS owns the global rights to all three
of these programmes.

There is a significant opportunity for CeNeS in realising the clinical and
commercial potential of M6G as an effective analgesic with a good side effect
profile. In light of these positive results the Company is considering its
financing options for taking this product forward, including equity funding and/
or out-licensing.

Overall, CeNeS is building a balanced, focused pipeline which is being
effectively managed by our in-house experts as evidenced by the successful
clinical progress we have made. CeNeS is also encouraged by additional novel
early stage opportunities that are being identified by our discovery team that
fit our focused 'risk-reduced' selection criteria.


The Board is confident that the Company's clear strategic focus coupled with the
excellent progress made to date in 2004 leaves CeNeS well placed to deliver
increased value to shareholders going forward.'



Contact details:

FOR TODAY ONLY:
Mary Clark - Capital MS&L - 0207 903 1000.

After today contact details are:

CeNeS Pharmaceuticals plc
Alan Goodman/Neil Clark
Tel: +44 (0)1223 266466
Fax: +44 (0)1223 266467
Capital MS&L

Mary Clark/Paula Crymble
Tel: +44 (0)20 7878 3181
Fax: +44 (0)20 7878 3184

Review of the six months ended 30 June 2004